Amneal acquires saol therapeutics' baclofen franchise

Bridgewater, n.j. & roswell, ga.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal”) and saol therapeutics, a private specialty pharmaceutical company (“saol”), today announced a definitive agreement under which amneal will acquire saol's baclofen franchise, including lioresal® and lyvispahtm as well as a pipeline product under development. the acquisition expands amneal's commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in
AMRX Ratings Summary
AMRX Quant Ranking